Corrigendum.
Authors: PMID: 29788773 [PubMed - as supplied by publisher] (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - May 24, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?
Authors: Munir KM, Davis SN PMID: 29788782 [PubMed - as supplied by publisher] (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - May 24, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Expression of Concern.
Authors: PMID: 29771171 [PubMed - as supplied by publisher] (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - May 19, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.
Authors: Negredo E, Clotet B Abstract INTRODUCTION: HIV eradication is not feasible and lifelong treatment is warranted to manage HIV infection. In this scenario, the advent of single-tablet, once-daily, fixed-dose co-formulations is important for reducing pill burden and maximize long-term drug adherence. Cobicistat-boosted darunavir along with emtricitabine and tenofovir alafenamide co-formulation (DRV/c/FTC/TAF or the trade name Symtuza®) is the first marketed protease inhibitor-based fixed-dose combination regimen for the treatment of HIV infection. It was approved in late 2017 by the European Medical Agenc...
Source: Expert Opinion on Pharmacotherapy - May 17, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Everolimus in treatment of neuroendocrine tumors: efficacy, side-effects, resistance and factors affecting its place in the treatment sequence.
Authors: Lee L, Ito T, Jensen RT Abstract INTRODUCTION: Since the initial approval of everolimus in 2011, there have been a number of important changes in therapeutic/diagnostic modalities as well as classification/staging systems of neuroendocrine tumors (NETs), which can significantly impact the use of everolimus in patients with advanced NETs. Areas covered: The efficacy of everolimus monotherapy and combination therapy demonstrated in clinical studies involving patients with advanced NETs are reviewed. Several factors affecting everolimus' use are described including: the development and routine use of NET clas...
Source: Expert Opinion on Pharmacotherapy - May 16, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?
Authors: Liao BC, Lin CC, Yang JC Abstract INTRODUCTION: Brain metastases (BMs) develop in up to 40% of patients with non-small cell lung cancer (NSCLC). In many recent practice-changing clinical trials, patients with BM were included; however, only few trials reported intracranial efficacies in either post hoc or pre-planned analysis. Clinically meaningful intracranial efficacy data of novel agents have not been completely disclosed. Areas covered: The authors performed a systemic review of recent pharmaceutical clinical trials, mainly pivotal or practice-changing trials. Some of the prospective clinical trials fo...
Source: Expert Opinion on Pharmacotherapy - May 7, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Pharmacotherapy for the treatment of depression in patients with alzheimer's disease: a treatment-resistant depressive disorder.
Authors: Lozupone M, La Montagna M, D'Urso F, Piccininni C, Sardone R, Dibello V, Giannelli G, Solfrizzi V, Greco A, Daniele A, Quaranta N, Seripa D, Bellomo A, Logroscino G, Panza F Abstract INTRODUCTION: Pharmacotherapy for the treatment of depressive disorders in Alzheimer's Disease (AD) represents a clinical challenge. pharmacological options are often attempted after a period of watchful waiting (8-12 weeks). monoaminergic antidepressant drugs have shown only modest or null clinical benefits, maybe because the etiology of depressive symptoms in ad patients is fundamentally different from that of nondement...
Source: Expert Opinion on Pharmacotherapy - May 7, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Alcoholic steatohepatitis (ASH) and alcoholic hepatitis (AH): cascade of events, clinical aspects, and pharmacotherapy options.
This article covers metabolic aspects of alcohol as the basis of understanding pharmacotherapy and to facilitate choosing the drug therapeutic options for patients with severe AH. Expert opinion: Alcoholic steatohepatitis (ASH) and alcoholic hepatitis (AH) as terms are often used interchangeably in scientific literature but a stringent differentiation is recommended for proper clarity. As opposed to ASH, the clinical course of AH is often severe and requires an effective drug treatment strategy, in addition to absolute alcohol abstinence and nutritional support. Drug options include corticosteroids as a first choice and pe...
Source: Expert Opinion on Pharmacotherapy - May 2, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia.
Authors: Michaelis LC, Klepin HD, Walter RB Abstract INTRODUCTION: Treating acute myeloid leukemia (AML) in older adults remains daunting. The unique biology often renders conventional chemotherapies less effective. Accurately predicting the toxicities of treatment is another unresolved challenge. Treatment planning thus requires a good knowledge of the current trial data and familiarity with clinical tools, including formal fitness and geriatric assessments. Both obstacles - disease biology and patient fitness - might be easier overcome with specific, AML cell-targeted agents rather than traditional cytotoxic chem...
Source: Expert Opinion on Pharmacotherapy - April 27, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Novel fluoropyrimidine-based chemotherapy for advanced well-differentiated neuroendocrine tumors: a clinical update.
Authors: Zhang H, Shen G, Zhang S, Du F, Cao Y, Jiang J, Zheng F, Ma X, Wang Z, Ren D, Ahmad R, Zhao F, Zhao J Abstract INTRODUCTION: Patients with advanced well-differentiated neuroendocrine tumors (NETs) who have bulky and/or symptomatic and/or rapidly progressive disease require chemotherapy treatment. Areas covered: This review summarizes the accumulating evidence for treatment with fluorouracil-based chemotherapy in well-differentiated NETs. The main clinical studies, toxicity and predictors of fluorouracil- based chemotherapy regimens in well-differentiated NETs are discussed, along with the current issues, f...
Source: Expert Opinion on Pharmacotherapy - April 26, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Current and emerging two-drug approaches for HIV-1 therapy in ART-na ïve and ART-experienced, virologically suppressed patients.
Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients. Expert Opin Pharmacother. 2018 Apr 20;:1-26 Authors: Rossetti B, Montagnani F, De Luca A Abstract INTRODUCTION: Current guidelines recommend a 2-drug antiretroviral regimen as an alternative to triple antiretroviral therapy (ART) in selected patients to reduce long-term toxicity and costs. Areas covered: This review is intended to provide insight into the efficacy, safety and tolerability of 2-drug versus 3-drug ART in naïve and in treatment-experienced virologically...
Source: Expert Opinion on Pharmacotherapy - April 22, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Pharmacotherapy for schizophrenia in postmenopausal women.
Authors: González-Rodríguez A, Seeman MV Abstract INTRODUCTION: Reduced estrogen levels at menopause mean a loss of the neuroprotection that is conferred, from puberty until menopause, on women with schizophrenia. The postmenopausal stage of schizophrenia requires therapeutic attention because women with this diagnosis almost invariably experience increased symptoms and increased side effects at this time. So far, few targeted therapies have been successfully developed. Areas covered: This non-systematic, narrative review is based on the relevant published literature indexed in PubMed. A digital searc...
Source: Expert Opinion on Pharmacotherapy - April 22, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

What is the impact of the 2017 Cochrane Systematic Review and Meta-Analysis that evaluated the use of PCSK9 Inhibitors for lowering cardiovascular disease and mortality?
Authors: Jalloh MA, Ip EJ, Doroudgar S Abstract INTRODUCTION: In 2017, Schmidt et al. conducted a Cochrane systematic review and meta-analysis to evaluate the effect of using proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to reduce low-density-lipoprotein- cholesterol (LDL-C) and cardiovascular disease (CVD). The Cochrane review was a systematic review and meta-analysis of 20 randomized, double-blinded trials that compared the use of PCSK9 inhibitors with statins/ezetimibe, ezetimibe, or placebo for a treatment duration of at least 24 weeks. The use of PCSK9 inhibitors lowered the risk for CVD (OR...
Source: Expert Opinion on Pharmacotherapy - April 20, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Rucaparib: a new treatment option for ovarian cancer.
Authors: Sabatucci I, Maltese G, Lepori S, Tripodi E, Bogani G, Lorusso D Abstract INTRODUCTION: Approximately 50% of high-grade serous ovarian cancers present a deficiency in the pathways involved in homologous recombination (HR). PARP inhibitors prevent single-strand DNA damage repair and determine a progression of the defect towards double-strand breaks, which results in a process known as 'synthetic lethality'. Areas covered: In this review, the authors discuss the efficacy and toxicity of rucaparib either as a single agent or as a maintenance treatment for ovarian cancer. This includes the NGS Foundation Medic...
Source: Expert Opinion on Pharmacotherapy - April 20, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Extended-release drug formulations for the treatment of epilepsy.
Authors: Brandt C, May TW Abstract INTRODUCTION: Extended-release (ER) preparations are either available or have been tested for several antiepileptic drugs (AEDs). Indeed, they may be helpful in improving efficacy, tolerability, adherence, compared to the corresponding immediate release (IR) preparations available. The use of ER preparations has been advocated in women of childbearing age and is - depending on the drug - especially helpful in patients who are treated in combination with enzyme inducing AEDs as well as in children. Areas covered: Clinical and pharmacokinetic studies on ER formulations of AEDs were ...
Source: Expert Opinion on Pharmacotherapy - April 20, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

An update and systematic review on drug therapies for the treatment of refractory chronic cough.
Authors: Ryan NM, Vertigan AE, Birring SS Abstract INTRODUCTION: Chronic Cough (CC) is common and often associated with significant comorbidity and decreased quality of life. In up to 50% of cases, the cough is refractory despite extensive investigation and treatment trials. It is likely that the key abnormality in refractory CC is dysfunctional, hypersensitive sensory nerves, similar to conditions such as laryngeal hypersensitivity and neuropathic pain. Areas covered: The aim of this systematic review is to assess drug therapies for refractory CC. The authors review the current management of CC and provide discuss...
Source: Expert Opinion on Pharmacotherapy - April 17, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Levonorgestrel-releasing intra-uterine systems as female contraceptives.
Authors: Grandi G, Farulla A, Sileo FG, Facchinetti F Abstract INTRODUCTION: The availability and use of long-acting reversible contraceptives (LARCs), such as levonorgestrel intrauterine systems (LNG-IUSs), have increased in recent times. Areas covered: The authors provide a narrative review of the LNG-IUSs currently available worldwide as female contraceptives (LNG-IUS 13.5, 19.5 and 52 mg). Specific features of the devices and their parameters of efficacy and tolerability were considered as outcomes. Expert opinion: The one-handed 3.8-mm-diameter inserter of LNG-IUS 13.5 mg and 19.5 mg may be part...
Source: Expert Opinion on Pharmacotherapy - April 13, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Masitinib in treatment of pancreatic cancer.
Authors: Waheed A, Purvey S, Saif MW Abstract INTRODUCTION: Pancreatic cancer continues to have high mortality despite the development of many chemotherapeutic agents. The 5-year relative survival for stage IV patients is less than 3%. This urgent unmet need warrants the development of novel and active therapeutic agents, which focus both on targeting cancer cells and modifying the microenvironment of cancer cells. Areas covered: In this article, the authors review the development of masitinib, a novel tyrosine kinase inhibitor of numerous targets, including c-Kit, PDGFR and FGFR. This review covers its development...
Source: Expert Opinion on Pharmacotherapy - April 13, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Intravenous carbamazepine for the treatment of epilepsy.
Authors: Brigo F, Leo A, Russo E, Striano P, Belcastro V Abstract INTRODUCTION: Recently, an intravenous formulation of carbamazepine (CBZ) (sulphobutylether-7-beta-cyclodextrine carbamazepine, SBECD CBZ) has been developed and approved by the U.S. Food and Drug Administration. It is indicated as a short-term replacement therapy for oral CBZ formulations, when oral administration is temporarily not feasible and in adults with focal seizures with complex symptomatology as well as generalized tonic-clonic seizures and mixed seizure patterns. Areas covered: This review focuses on the drug development, pharmacokinetics...
Source: Expert Opinion on Pharmacotherapy - April 13, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.
This article reviews the studies leading to the approval of the combination, and its efficacy and safety profile. Expert opinion: Sofosbuvir/velpatasvir/voxilaprevir fills one of the previously unfilled niches for the treatment of hepatitis C, that of the treatment of individuals who have failed therapy with resistant virus. With the filling of this niche, there appears to be a general slowing of the development of new therapeutics. Although understandable, in the long term, there are considerable risks associated with the decreased development of new drugs to treat hepatitis C. PMID: 29634360 [PubMed - as supplied by ...
Source: Expert Opinion on Pharmacotherapy - April 12, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Combination Oral Antithrombotic Therapy for the Treatment of Myocardial Infarction: Recent Developments.
Authors: Tantry US, Navarese EP, Myat A, Chaudhary R, Gurbel PA Abstract INTRODUCTION: There have been significant new developments in the treatment of patients with myocardial infarction with respect to oral antithrombotic agents over the past decade. Recent studies have explored the potential utility of targeting the dual pathway inhibition of platelet function with single or dual antiplatelet agents and the thrombin pathway with direct thrombin inhibitors or factor Xa inhibitors. Areas covered: In this review, the authors focus on the recent developments of oral antithrombotic agents including antiplatelet and a...
Source: Expert Opinion on Pharmacotherapy - April 5, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Improvement in the proinsulin/C-peptide ratio during treatment with ipragliflozin in Japanese patients with type 2 diabetes mellitus.
Authors: Takase T, Nakamura A, Yamamoto C, Atsumi T, Miyoshi H PMID: 29591723 [PubMed - as supplied by publisher] (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - March 31, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Protease inhibitor therapy for hepatitis C virus-infection.
Authors: de Leuw P, Stephan C Abstract INTRODUCTION: The hepatitis C virus (HCV) has affected an estimated of 80 million individuals worldwide and is a strain on public health. Around 25-30% of patients in Europe and the US who are infected with HIV are coinfected with HCV. Prior to 2013, treatment modalities containing an NS3/4A protease inhibitor in combination with pegylated interferon and ribavirin improved sustained virological response (SVR) rates. However, rates of severe side effects were high. Nowadays, oral direct-acting antiviral (DAA) combination therapy offers excellent treatment efficacy, safety and t...
Source: Expert Opinion on Pharmacotherapy - March 31, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Psychotropic medications for highly vulnerable children.
Authors: McLaren JL, Barnett ER, Concepcion Zayas MT, Lichtenstein J, Acquilano SC, Schwartz LM, Woloshin S, Drake RE Abstract INTRODUCTION: At least 20% of children in the U.S. are highly vulnerable because they lack healthcare and protection. Several factors produce vulnerability: trauma, disruptions of parenting, poverty, involvement in the juvenile justice and/or child welfare systems, residence in restrictive settings, and problems related to developmental disabilities. These children receive psychotropic medications at high rates, raising numerous concerns. Areas covered: The authors begin this review with a ...
Source: Expert Opinion on Pharmacotherapy - March 31, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Pharmacotherapeutic strategies for treating hypertension in patients with obesity.
Authors: Carnagarin R, Matthews V, Gregory C, Schlaich MP Abstract INTRODUCTION: Hypertension and obesity are important health challenges that independently increase cardiovascular morbidity and mortality. There is a lack of randomized controlled trials to clearly inform on preferred drug choices to be adopted in clinical practice for the treatment of obesity-related hypertension (OHT). Adequate differentiation of drug classes for preferential use in obesity or the metabolic syndrome aimed at avoiding adverse effects on body weight and the metabolic profile is neglected in this population, at least in part due to t...
Source: Expert Opinion on Pharmacotherapy - March 31, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

An update on treatment for post-menopausal metastatic breast cancer in elderly patients.
Authors: Menjak IB, Jerzak KJ, Desautels DN, Pritchard KI Abstract INTRODUCTION: Elderly patients make up a significant proportion of patients with metastatic breast cancer. With several options available in the metastatic setting for hormone positive breast cancer, these patients require an individualized approach to decision-making that considers multiple factors beyond performance status and chronologic age. Areas covered: The authors review the literature on endocrine monotherapy and combinations for hormone positive metastatic breast cancer, with specific commentary on the efficacy and toxicity for elderly pat...
Source: Expert Opinion on Pharmacotherapy - March 31, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Advances in chemical pharmacotherapy for the treatment of pediatric immune thrombocytopenia.
Authors: Kühne T Abstract INTRODUCTION: Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder of heterogeneous pathophysiological mechanisms. Treatment endpoints include elevation of platelets and reduction of bleeding risk, elevation of quality of life, reduction of concomitant therapies and prevention from bleeding. Persistent and chronic ITP is more common in adults but occurs in children. Standard therapies include corticosteroids and immunoglobulins, both associated with side effects. There are new treatments, such as thrombopoietin-receptor agonists and promising investigational drugs. Areas c...
Source: Expert Opinion on Pharmacotherapy - March 30, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Are traditional approaches diminishing the bipolar drug pipeline?
Authors: Bowden C, Martinez M PMID: 29565182 [PubMed - as supplied by publisher] (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - March 28, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas.
Authors: Kivelevitch D, Frieder J, Watson I, Paek SY, Menter MA Abstract INTRODUCTION: Despite great therapeutic advancements in psoriasis, four notable difficult-to-treat areas including the scalp, nails, intertriginous (including genitals), and palmoplantar regions, pose a challenge to both physicians and patients. Localized disease of these specific body regions inflicts a significant burden on patients' quality of life and requires an adequate selection of treatments. Areas covered: This manuscript discusses appropriate therapies and important treatment considerations for these difficult-to-treat areas based on...
Source: Expert Opinion on Pharmacotherapy - March 28, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Pharmacotherapy for chronic non-specific low back pain: current and future options.
Authors: Koes BW, Backes D, Bindels PJE Abstract INTRODUCTION: Low back pain is associated with a large burden-of-illness. It is responsible for the most years lived with disability as compared with any other medical condition. A comprehensive overview of the evidence on pharmacological treatment options for chronic low back pain is lacking. This review evaluates the evidence for the benefits and risks of currently available pharmacological treatments for chronic low back pain. Areas covered: The authors focus on the recent (Cochrane) systematic reviews and meta-analyses of randomized clinical trials covering parac...
Source: Expert Opinion on Pharmacotherapy - March 28, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Drug treatment of hypertension in older patients with diabetes mellitus.
Authors: Yandrapalli S, Pal S, Nabors C, Aronow WS Abstract INTRODUCTION: Hypertension is more prevalent in the elderly (age>65 years) diabetic population than in the general population and shows an increasing prevalence with advancing age. Both diabetes mellitus (DM) and hypertension are independent risk factors for cardiovascular (CV) related morbidity and mortality. Optimal BP targets were not identified in elderly patients with DM and hypertension. Areas covered: In this review article, the authors briefly discuss the pathophysiology of hypertension in elderly diabetics, present evidence with various an...
Source: Expert Opinion on Pharmacotherapy - March 28, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Next generation fixed dose combination pharmacotherapies for treating HIV.
Authors: Caplan MR, Daar ES, Corado KC Abstract INTRODUCTION: Treatment options for patients with HIV-1 infection have grown over the past two decades to include multiple fixed-dose combination pharmacotherapies that have greatly simplified administration of antiretroviral therapy (ART) for both patients and providers. Effective virologic control can often be achieved with once-daily use of a single-tablet regimen. Over the past three years, ART drug development has focused on the next generation of fixed-dose combinations for initial and maintenance therapy with improved efficacy, safety and tolerability. Areas co...
Source: Expert Opinion on Pharmacotherapy - March 21, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Pharmacotherapy of retinal disease with visual cycle modulators.
Authors: Hussain RM, Gregori NZ, Ciulla TA, Lam BL Abstract INTRODUCTION: Pharmacotherapy with visual cycle modulators (VCMs) is under investigation for retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt macular dystrophy (SMD) and nonexudative age-related macular degeneration (AMD), all blinding diseases that lack effective treatment options. Areas covered: The authors review investigational VCMs, including oral retinoids, 9-cis-retinyl-acetate (zuretinol) and 9-cis-β-carotene, which restore 11-cis-retinal levels in RP and LCA caused by LRAT and RPE65 gene mutations, and may improve visual...
Source: Expert Opinion on Pharmacotherapy - March 17, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Ivermectin 1% (CD5024) for the treatment of rosacea.
This article provides an in-depth review of rosacea treatment and emerging use of ivermectin 1% cream for papulopustular rosacea based on multiple clinical trials. The PubMed database was searched using the combination of keywords "ivermectin, rosacea, and papulopustular." Expert opinion: Topical ivermectin 1% cream has emerged as a novel agent for treatment of papulopustular rosacea. The drug targets the Demodex mite which is increased in patients with rosacea. Though ivermectin 1% is a clinically efficacious medication, poor adherence continues to remain an issue due to topical application. Ultimately, the agen...
Source: Expert Opinion on Pharmacotherapy - March 17, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Efficacy of dapagliflozin as an adjunct therapy in patients with inadequately controlled type 1 diabetes mellitus.
Authors: Van den Mooter L, Caerels S, Mathieu C Abstract INTRODUCTION: There is a clear unmet clinical need in people with Type 1 diabetes (T1DM) considering present day insulin therapy. New insulin analogues and novel technologies allowing more tailored insulin administration have improved the quality of life of people with T1DM, but issues like hypoglycemia, weight gain and variability in glucose profiles remain problematic. Areas covered: In this review, the clinical efficacy, safety and tolerability of dapagliflozin, a sodium-glucose cotransporter type 2 inhibitor, in type 1 diabetes (T1DM) is described based o...
Source: Expert Opinion on Pharmacotherapy - March 16, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer.
Authors: Mulet N, Matos I, Noguerido A, Martini G, Élez ME, Argilés G, Tabernero J Abstract INTRODUCTION: Despite major progress in treating advanced colorectal cancer (CRC), prognosis in this population after progression on standard treatment remains dismal and the development of new drugs represents an unmet need. Historically, fluoropyrimidines have played a major role in the treatment of metastatic CRC. TAS-102, a novel combination of trifluridine and tipiracil hydrochloride, has demonstrated improvement in overall survival in the refractory CRC setting, with a safe toxicity profile. Areas covered...
Source: Expert Opinion on Pharmacotherapy - March 16, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.
Authors: Rommer PS, Zettl UK Abstract INTRODUCTION: Multiple sclerosis (MS) is an immune-mediated and neurodegenerative disease with an unpredictable outcome. Immune-modulatory treatment aims at decreasing long-term disability. With the increasing number of treatment options, it is essential to fully digest the possible side effects of the available therapeutics and to monitor patients is essential. Areas covered: All approved disease-modifying drugs (DMD) for MS are discussed in this review. Mode of action, adverse effects, reported risks for infections and malignancies, and pregnancy related issues are discussed ...
Source: Expert Opinion on Pharmacotherapy - March 14, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Abemaciclib for the treatment of breast cancer.
Authors: Kotake T, Toi M Abstract INTRODUCTION: There have been numerous clinical trials of CDK4/6 inhibitors performed on various carcinomas including breast cancer. One such inhibitor tested and which has ongoing clinical trials for breast cancer is abemaciclib. Abemaciclib is a molecular-targeted agent that targets basic cell cycle regulatory mechanisms. Areas covered: This review discusses the available clinical data and ongoing clinical trials of abemaciclib in breast cancer. Expert opinion: Abemaciclib has demonstrated a clear anti-tumour effect and manageable toxicity against HR-positive, HER2-negative breas...
Source: Expert Opinion on Pharmacotherapy - March 11, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.
Authors: Turco NJ, Kane-Gill SL, Hernandez I, Oleksiuk LM, D'Amico F, Pickering AJ Abstract INTRODUCTION: Acute bacterial skin and skin-structure infections (ABSSSI) are common infectious diseases (ID) that often require intravenous (IV) antibiotics. Dalbavancin is a novel lipoglycopeptide antibiotic administered once that is FDA-approved for the treatment of ABSSSI. No literature is available for real-world cost-comparability relative to conventional therapy. METHODS: This retrospective chart review examined adults diagnosed with ABSSSI and treated with IV antibiotics at an outpatient ID clinic after hospital ...
Source: Expert Opinion on Pharmacotherapy - March 7, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Cardiovascular outcomes trial with anacetrapib in subjects with high cardiovascular risk - are major benefits REVEALed?
Authors: Doggrell SA Abstract INTRODUCTION: The actions of the cholesteryl ester transfer protein (CETP) inhibitors (torcetrapib, dalcetrapib and evacetrapib) include increasing high-density lipoprotein (HDL) cholesterol, but they do not reduce cardiovascular outcomes in subjects with high cardiovascular risk. Anacetrapib also inhibits CETP, increases HDL cholesterol and lowers low-density lipoprotein (LDL) cholesterol. Areas Covered: This evaluation is of the REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid Modification) trial, which was a cardiovascular outcomes trial with anacetrapib in ...
Source: Expert Opinion on Pharmacotherapy - March 4, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Therapy for pruritus in the elderly: a review of treatment developments.
Authors: Pereira MP, Ständer S Abstract INTRODUCTION: The prevalence of chronic pruritus (CP) in the general population is high and increases with age. Owing to high rates of comorbidities and polypharmacy in patients aged 65 or older, the clinical management of these patients is challenging. Areas covered: In this review, the authors discuss the available therapy options for patients aged ≥ 65 with CP, including emollients for dry skin, topical therapies, phototherapy and systemic agents for CP of various origins. Expert opinion: For multimorbid patients, topical substances and phototherapy constitute the ...
Source: Expert Opinion on Pharmacotherapy - March 3, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Pharmacological interventions for psychosis in Parkinson's disease patients.
This article reviews the therapeutic approaches of this syndrome focusing on drug treatments used once contributory factors have been removed. This includes a review of the evidence supporting the use of clozapine and, most recently, pimavanserin, the first drug with antipsychotic efficacy that has no effect on dopamine. Treatment with second generation antipsychotic drugs and cholinesterase inhibitors are also reviewed. Expert opinion: Clozapine and pimavanserin have proven efficacy for Parkinson's disease psychosis (PDP), without impairing motor function. In clozapine's favor are its antipsychotic benefits seen within 1&...
Source: Expert Opinion on Pharmacotherapy - March 3, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Abiraterone is effective and should be considered for the treatment of metastatic castrate-na ïve prostate cancer.
Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer. Expert Opin Pharmacother. 2018 Mar 01;:1-3 Authors: Elkon JM, Millett RL, Millado KF, Lin J Abstract INTRODUCTION: Androgen deprivation therapy (ADT) has been the standard of care for the treatment of newly diagnosed metastatic prostate cancer for the past 70 years. Furthermore, adding docetaxel chemotherapy to ADT significantly improved patient survival, and thus became the new standard for patients with high volume disease. However, recent evidence has called this treatment stra...
Source: Expert Opinion on Pharmacotherapy - March 3, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Treating cardiovascular complications of radiotherapy: a role for new pharmacotherapies.
Authors: Donis N, Oury C, Moonen M, Lancellotti P Abstract INTRODUCTION: Available data indicate that survivors of breast cancer and Hodgkin lymphoma who received mediastinal radiotherapy are at increased risk of developing radiation-induced cardiovascular diseases (RICVD) one or two decades after treatment. Although the risk with modern radiation treatment is likely to be lower in these patient groups, cardiotoxicity is still observed in a subset of patients. In addition, radiation-associated cardiovascular complications can, in the future, extend to other groups of cancer patients who are treated for tumors that ...
Source: Expert Opinion on Pharmacotherapy - March 3, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Has flibanserin revolutionized the treatment of hypoactive sexual desire disorder or is there still room for more effective therapeutics?
Authors: Nappi RE, Cucinella L, Tiranini L, Martini E PMID: 29488405 [PubMed - as supplied by publisher] (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - March 1, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Direct Acting Antivirals for the Treatment of Hepatitis C in Ethnic Minority Populations.
Authors: Wilder JM, Muir A Abstract INTRODUCTION: Direct acting antivirals (DAA's) have revolutionized the treatment of hepatitis C (HCV). However, questions persist concerning their efficacy in minority populations. Areas covered: In this review, the authors review outcomes for treatment of HCV by race and ethnicity among the clinical trials that have led to the current recommended treatments for HCV. The authors highlight the efficacy and safety differences by race and ethnicity. They also highlight deficiencies within the literature including small populations of racial/ethnic minorities within HCV clinical tria...
Source: Expert Opinion on Pharmacotherapy - March 1, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Proteasome inhibitors for the treatment of multiple myeloma.
Authors: Scalzulli E, Grammatico S, Vozella F, Petrucci MT Abstract INTRODUCTION: Multiple Myeloma (MM) management is rapidly evolving, with a spectrum of novel treatments that have changed our approach to the therapy. Proteasome inhibitors (PIs) have revolutionized the scenario of both relapsed/refractory and newly diagnosed patients. The efficacy of bortezomib, the first PI approved, followed by carfilzomib and, the oral ixazomib, have been tested in several trials as single agents or in combination. Areas covered: In this review, the authors summarize mechanism of action, efficacy and safety of proteasome inhibi...
Source: Expert Opinion on Pharmacotherapy - February 28, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Current and future treatment options for community-associated MRSA infection.
Authors: Khan A, Wilson B, Gould IM Abstract INTRODUCTION: Community-associated MRSA (CA-MRSA) represents a global epidemic which beautifully encapsulates the fascinating ability of bacterial organisms to adapt quickly on an evolutionary basis to the extreme selective pressure of antibiotic exposure. In stark contrast to Healthcare-associated MRSA (HA-MRSA), it has become apparent that CA-MRSA is less straight forward of a challenge in terms of controlling its transmission, and has forced clinicians to adjust empiric management of clinical syndromes such as skin and soft tissue infection (SSTI) as well as pneumonia...
Source: Expert Opinion on Pharmacotherapy - February 28, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

A noninferiority confirmatory trial of prasugrel versus clopidogrel in Japanese patients with non-cardioembolic stroke: rationale and study design for a randomized controlled trial - PRASTRO-I trial.
CONCLUSIONS: This article presents the study design and rationale for a trial investigating the noninferiority of prasugrel to clopidogrel sulfate with regards to the inhibitory effect on primary events in patients with non-cardioembolic stroke. PMID: 29463150 [PubMed - as supplied by publisher] (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - February 25, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research

Glecaprevir + pibrentasvir for treatment of hepatitis C.
Authors: Carrion AF, Martin P Abstract Introduction Glecaprevir/pibrentasvir is a fixed-dose combination regimen of a new generation NS3/4A inhibitor and an NS5A inhibitor with potent antiviral activity against all hepatitis C virus (HCV) genotypes. This regimen offers a shorter course of therapy (8 weeks) for selected patients regardless of genotype and has demonstrated high virological efficacy for retreatment of individuals who previously failed an NS5A containing regimen. Glecaprevir and pibrentasvir are minimally excreted by the kidneys; thus this regimen can safely be used in individuals with severe chronic k...
Source: Expert Opinion on Pharmacotherapy - February 25, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research